Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The earnings per share (EPS) is N/A as of the fiscal period ended Tuesday, December 31, 2024.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.08.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 16 comparable quarters.
EARNINGS PER SHARE (EPS)
N/A
EARNINGS PER SHARE (EPS) AVG TTM
-1.30
EARNINGS PER SHARE (EPS) AVG 3Y
-1.38
EARNINGS PER SHARE (EPS) AVG 5Y
-1.95
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Opus Genetics, Inc.
Market Cap
$362.88M
Earnings Per Share (EPS)
N/A
TTM Avg
-1.30
3Y Avg
-1.38
5Y Avg
-1.95
Market Cap
$356.07M
Earnings Per Share (EPS)
-0.25
TTM Avg
-0.22
3Y Avg
-0.27
5Y Avg
-0.28
Market Cap
$357.78M
Earnings Per Share (EPS)
-2.41
TTM Avg
-4.66
3Y Avg
-5.40
5Y Avg
-4.56
Market Cap
$357.54M
Earnings Per Share (EPS)
1.48
TTM Avg
1.49
3Y Avg
2.03
5Y Avg
3.82
Market Cap
$356.43M
Earnings Per Share (EPS)
-3.31
TTM Avg
-3.43
3Y Avg
-2.65
5Y Avg
-2.61
Market Cap
$356.08M
Earnings Per Share (EPS)
-0.14
TTM Avg
-0.19
3Y Avg
-0.48
5Y Avg
-0.56
Market Cap
$353.48M
Earnings Per Share (EPS)
-0.92
TTM Avg
-2.05
3Y Avg
-3.17
5Y Avg
-3.94
Market Cap
$374.75M
Earnings Per Share (EPS)
-0.50
TTM Avg
-5.17
3Y Avg
-17.19
5Y Avg
-12.52
Market Cap
$350.90M
Earnings Per Share (EPS)
-0.99
TTM Avg
-1.39
3Y Avg
-1.39
5Y Avg
-0.93
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Opus Genetics, Inc. (IRD) | $362.88M | N/A | -1.30 | -1.38 | -1.95 |
| Ocugen, Inc. (OCGN)vs › | $356.07M | -0.25 | -0.22 | -0.27 | -0.28 |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $357.78M | -2.41 | -4.66 | -5.40 | -4.56 |
| Embecta Corp. (EMBC)vs › | $357.54M | 1.48 | 1.49 | 2.03 | 3.82 |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $356.43M | -3.31 | -3.43 | -2.65 | -2.61 |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $356.08M | -0.14 | -0.19 | -0.48 | -0.56 |
| Relmada Therapeutics, Inc. (RLMD)vs › | $353.48M | -0.92 | -2.05 | -3.17 | -3.94 |
| Canopy Growth Corporation (CGC)vs › | $374.75M | -0.50 | -5.17 | -17.19 | -12.52 |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $350.90M | -0.99 | -1.39 | -1.39 | -0.93 |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $378.94M | -3.33 | -2.70 | -1.54 | -2.91 |
Trailing EPS (TTM)
N/A
Forward EPS (Est.)
$-1.04
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2024-12-31 | -2.15 |
| 2023-12-31 | -0.46 |
| 2022-12-31 | 0.90 |
| 2021-12-31 | -3.82 |
| 2020-12-31 | -5.28 |
| 2019-12-31 | -0.87 |
